Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2003 May;72(5):1117-30.
doi: 10.1086/375033. Epub 2003 Apr 3.

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

A Antoniou  1 , P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg, B Pasini, P Radice, S Manoukian, D M Eccles, N Tang, E Olah, H Anton-Culver, E Warner, J Lubinski, J Gronwald, B Gorski, H Tulinius, S Thorlacius, H Eerola, H Nevanlinna, K Syrjäkoski, O-P Kallioniemi, D Thompson, C Evans, J Peto, F Lalloo, D G Evans, D F Easton
Affiliations
Meta-Analysis

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

A Antoniou et al. Am J Hum Genet. 2003 May.

Erratum in

  • Am J Hum Genet. 2003 Sep;73(3):709

Abstract

Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the average magnitude of these risks is uncertain and may depend on the context. Estimates based on multiple-case families may be enriched for mutations of higher risk and/or other familial risk factors, whereas risk estimates from studies based on cases unselected for family history have been imprecise. We pooled pedigree data from 22 studies involving 8,139 index case patients unselected for family history with female (86%) or male (2%) breast cancer or epithelial ovarian cancer (12%), 500 of whom had been found to carry a germline mutation in BRCA1 or BRCA2. Breast and ovarian cancer incidence rates for mutation carriers were estimated using a modified segregation analysis, based on the occurrence of these cancers in the relatives of mutation-carrying index case patients. The average cumulative risks in BRCA1-mutation carriers by age 70 years were 65% (95% confidence interval 44%-78%) for breast cancer and 39% (18%-54%) for ovarian cancer. The corresponding estimates for BRCA2 were 45% (31%-56%) and 11% (2.4%-19%). Relative risks of breast cancer declined significantly with age for BRCA1-mutation carriers (P trend.0012) but not for BRCA2-mutation carriers. Risks in carriers were higher when based on index breast cancer cases diagnosed at <35 years of age. We found some evidence for a reduction in risk in women from earlier birth cohorts and for variation in risk by mutation position for both genes. The pattern of cancer risks was similar to those found in multiple-case families, but their absolute magnitudes were lower, particularly for BRCA2. The variation in risk by age at diagnosis of index case is consistent with the effects of other genes modifying cancer risk in carriers.

PubMed Disclaimer

Figures

Figure  1
Figure  1
Kaplan-Meier cumulative breast (upper lines) and ovarian (lower lines) cancer probability in sisters (thick lines) and mothers (thin lines) of BRCA1-mutation–carrying index case patients.
Figure  2
Figure  2
Kaplan-Meier cumulative breast (upper lines) and ovarian (lower lines) cancer probability in sisters (thick lines) and mothers (thin lines) of BRCA2-mutation–carrying index case patients.
Figure  3
Figure  3
Cumulative risk of breast (♦) and ovarian (▪) cancer in BRCA1-mutation carriers.
Figure  4
Figure  4
Cumulative risk of breast (♦) and ovarian (▪) cancer in BRCA2-mutation carriers.
See this image and copyright information in PMC

Similar articles

  • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
    Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC; BRCA1 and BRCA2 Cohort Consortium; McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Kuchenbaecker KB, et al. JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112. JAMA. 2017. PMID: 28632866
  • Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Risch HA, et al. Am J Hum Genet. 2001 Mar;68(3):700-10. doi: 10.1086/318787. Epub 2001 Feb 15. Am J Hum Genet. 2001. PMID: 11179017 Free PMC article.
  • Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Risch HA, et al. J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706. doi: 10.1093/jnci/djj465. J Natl Cancer Inst. 2006. PMID: 17148771
  • Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ, Bewtra C. Casey MJ, et al. Fam Cancer. 2004;3(3-4):265-81. doi: 10.1007/s10689-004-9554-y. Fam Cancer. 2004. PMID: 15516851 Review.
  • Genetic Tests for Breast and Ovarian Cancer [Internet].
    Juvet LK, Natvig Norderhaug I. Juvet LK, et al. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008. PMID: 29319983 Free Books & Documents. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

Electronic-Database Information

    1. Breast Cancer Information Core, http://research.nhgri.nih.gov/bic/
    1. Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for BRCA1 and BRCA2)

References

    1. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 in a population based series of breast cancer cases. Br J Cancer 83:1301–1308 - PMC - PubMed
    1. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A (2000) Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 36:1200–1208 - PubMed
    1. Antoniou AC, Gayther SA, Stratton JF, Ponder BAJ, Easton DF (2000) Risk models for familial breast and ovarian cancer. Genet Epidemiol 18:173–190 - PubMed
    1. Antoniou AC, Pharoah PDP, McMullen G, Day NE, Ponder BAJ, Easton DF (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population based study. Genet Epidemiol 21:1–18 - PubMed
    1. Basham VM, Lipscombe JP, Ward JM, Easton DF, Gayther SA, Ponder BAJ, Pharoah PDP (2002) BRCA1 and BRCA2 mutations in a population based study of male breast cancer. Breast Cancer Res 4:R2.1–R2.4 - PMC - PubMed

Publication types

MeSH terms